Phorbol 12-myristate 13-acetate (PMA)-mediated signalling was investigated in relation to the ability of murine (CBA) bone marrow cells to form colonies in vitro. Treatment of marrow cells with PMA did not influence the 1,2-diacylglycerol or cyclic AMP concentrations, the intracellular Ca2+ concentration or phospholipase D activity. PMA increased particulate phospholipase A2 (PLA2) activity, lysophosphatidylcholine formation and arachidonic acid release from bone marrow cells; these effects were abolished when cells were pretreated with the putative PLA2 inhibitors heparin and mepacrine. While indomethacin and nordihydroguaiaretic acid inhibited either the cyclo-oxygenase or lipoxygenase pathway of arachidonic acid metabolism, as measured by their products prostaglandin E2 and leukotriene B4, they did not influence PMA-mediated PLA2 activation or translocation of protein kinase C (PKC) from the soluble to the particulate fraction. Treatment This signalling pathway appears to be mitogenic for bone marrow cells.
Phorbol 12-myristate 13-acetate (PMA)-mediated signalling was investigated in relation to the ability of murine (CBA) bone marrow cells to form colonies in vitro. Treatment of marrow cells with PMA did not influence the 1,2-diacylglycerol or cyclic AMP concentrations, the intracellular Ca2+ concentration or phospholipase D activity. PMA increased particulate phospholipase A2 (PLA2) activity, lysophosphatidylcholine formation and arachidonic acid release from bone marrow cells; these effects were abolished when cells were pretreated with the putative PLA2 inhibitors heparin and mepacrine. While indomethacin and nordihydroguaiaretic acid inhibited either the cyclo-oxygenase or lipoxygenase pathway of arachidonic acid metabolism, as measured by their products prostaglandin E2 and leukotriene B4, they did not influence PMA-mediated PLA2 activation or translocation of protein kinase C (PKC) from the soluble to the particulate fraction. Treatment Short-term exposure (45 min) of bone marrow cells to PMA, phorbol 12,13-dibutyrate or arachidonic acid increased the number of colonies formed over 7 days in a methylcellulosebased culture in vitro. The effects of PMA, but not those of arachidonic acid, could be prevented by putative PLA2 inhibitors.
INTRODUCTION
The protein kinases C (PKCs) constitute a family of phospholipid-dependent and diacylglycerol (DAG)-activated protein kinases which play key roles in signal transduction and cell regulation [1] . PKC isoenzymes exhibit distinct tissue distribution patterns, with most cell types expressing more than one PKC isotype. These isoenzymes have been grouped into three functional classes depending on their requirements for phosphatidylserine, calcium and DAG. The first group, the conventional PKCs (cPKCs; isoforms a, /31, /32 and y), require Ca2+ and DAG to be activated, whereas the second group, the novel PKCs (nPKCs; isoforms 8, e, 0 and q), are Ca2+-independent [1, 2] . Common features of the C1 domain ofcPKCs and nPKCs are a conserved pseudosubstrate site and two adjacent N-terminal cysteine clusters which are responsible for phorbol ester binding. The stimulation of PKCs by phorbol 12-myristate 13-acetate (PMA) has been widely used in studies of PKC-mediated cell signalling [1, 2] . More recently, the third group, termed the atypical PKCs (aPKCs; isoforms C, A, t and ,) has been identified. aPKCs are dependent on phosphatidylserine, but are not affected by DAG, phorbol esters or Ca21 [1, 3] .
All mature blood cells in the body are derived from pluripotent stem cells which generate lineage-restricted progenitor cells through the process of differentiation. Haematopoiesis is regulated by a series of soluble and membrane-bound molecules which act on responding cells via specific membrane receptors [4, 5] . Although many haemopoietic growth factors have been purified to homogeneity and their genes cloned, post-receptor signalling events elicited by the occupation of their respective receptors remain only partially described [4] [5] [6] . The role of PKC in haematopoietic cell function has been widely examined and it has been shown that proliferation, differentiation and colony formation of both normal and leukaemic haematopoietic cells can be stimulated by treatment of the cells with PMA [2, 4, 7, 8] . Therefore the aim of the present study was to investigate PMAmediated signalling in murine bone marrow cells and to compare it with the ability of the cells to form colonies in vitro. Mass assay of DAG DAG from the cells was extracted using 1.5 ml of chloroform/ methanol (1:2, v/v). Further extraction was performed as described by Folch et al. [9] . The lipid extract was dissolved in 0.5 ml of chloroform and loaded on a silicic acid column (0.5 ml; made in a Pasteur pipette), eluted with 1 ml of chloroform, dried again and the mass measurement for DAG was performed using DAG kinase whose purification was achieved in a single step from rat brain using DEAE-Sepharose column as described by Divecha and Irvine [10] .
MATERIALS AND METHODS
The chloride, washed and incubated as described above. After incubation, cells were quenched with chloroform/methanol (1 :2, v/v). A mixture of unlabelled lysoPtdCho and PtdCho was added at this stage for localization of the products by TLC. Lipids were extracted as described by Folch et al. [9] and chromatographed on TLC plates using the solvent system chloroform/methanol/7 M NH3 (12:7: 1, by vol.). Lipids were visualized using iodine vapour and the spots corresponding to lysoPtdCho and PtdCho standards were scraped off and their 3H content determined by scintillation counting.
Determination of PKC
Particulate and soluble fractions from bone marrow cells were prepared as described above (for the determination of PLA2 activity), particulate PKC was extracted from the membranes using 0.1 %0 Triton X-l00 and PKC activity was determined by a modification of the method used by Dawson and Cook [14] . The sample (50 j1; protein concentration 2 mg/ml) was added into 150 ,ul of buffer for determination of PKC activity (20 mM Tris, 40 mM magnesium acetate, 25 ,ug of histone IIIS, 0.75 mM CaCl2, pH 7.5) also containing 100 ,M ATP and-1 ,sCi of-[32P]ATP. The mixture was incubated at 30°C for 5 min with or without 24 ,ug of phosphatidylserine and 0.8 ,tg of diolein. The reaction was stopped by adding 1 ml of ice-cold 50% (w/v) trichloroacetic acid. Radioactivity incorporated into the histone was trapped on filters (0.45 ,um pore size) by washing twice with 3 ml of ice-cold 500 trichloroacetic acid. The filters with the remaining radioactivity were then placed into scintillation vials and radioactivity was measured by liquid scintillation counting. PKC activity was taken as the difference in counts of 32P between samples with activators (phosphatidylserine and diolein) and without them (control).
SDS/PAGE and Immunoblotting
Proteins for electrophoresis were prepared so that the concentration of each sample was 50 ug/25 ,ul of sample loading buffer [15] . Electrophoresis was carried out using a Bio-Rad Minigel apparatus at an acrylamide concentration of 10 % (w/v).
After electrophoresis, the proteins were transferred to nitrocellulose using a Bio-Rad wet-blotting system. After blocking the nitrocellulose in 20 mM Tris, 140 mM NaCl, 0.05 % (v/v) Tween 20 and 4 % (w/v) dried milk (Marvel), the blots were incubated with primary antibody (1: 1000) for 2 h, washed in the above buffer and incubated with the secondary antibody conjugated to horseradish peroxidase. Visualization was carried out using the ECL kit (Amersham). Measurements of cAMP, PGE2, LTB4 and proteins cAMP, PGE2 and LTB4 were determined as described using commercial kits (Amersham). Proteins were determined by the Bradford method [16] . (1 ,uM) significantly increased the DAG concentration, as well as the amount of radioactivity found in PtdOH and PtdEt. On the other hand, simultaneous 10 min treatment of cells with both PMA (500 nM) and A23187 (1 ,uM) did not produce any further increase in the concentration and the radioactivity of the compounds mentioned above when compared with the cells stimulated by ionophore alone (results not shown). Figure 2 shows the time-and dose-dependent activation of membrane-bound PLA2. At Since it is known that the free concentration of Ca2+ in the homogenization buffer can influence the cellular distribution of PLA2 [18] , the concentration of free Ca2+ in both the homogenization and PLA2 assay buffers was adjusted to 150 nM, which is similar to the measured [Ca2+]i (Figure 1 ). The assays were performed in the presence of 5 mM DTT to inactivate the secretory PLA2 [19] . It is important to note that under the experimental conditions described we were not able to observe any difference in soluble PLA2 activity between control and PMA-treated (500 nM over 30 min) groups (results not shown). Figure 3 shows that the inhibitors of PLA2, mepacrine and heparin [20, 21] , can diminish particulate PLA2 activity in both control and PMA-treated bone marrow cells. In the present study, heparin of low molecular mass (approx. 3000 Da) was used, and although it was introduced extracellularly, its intracellular effect on PLA2 activity might be explained by its endocytosis, which is known to occur in leukaemic haematopoietic cells [22] , and its partial release from endocytotic vesicles within the cell. When the inhibitors were applied together (mepacrine 500 ,uM + heparin 1 mg/ml), more than 80 % of initially measured particulate PLA2 activity in untreated cells could be inhibited (control, 17 + 40%; PMA-treated cells, 16 + 3 %o; all other details are as described in the legend to Figure 3) .
Statistical evaluation
Additional experiments in which phospholipids were prelabelled with arachidonic acid were performed and arachidonic acid release from bone marrow cells was monitored. Table 1 shows that the treatment ofcells with PMA significantly increased arachidonic acid release and formation of lysoPtdCho. Mepacrine and heparin diminished the release of arachidonic acid into the medium, as well as the radioactivity found in lysoPtdCho, in both control and PMA-treated groups, which is a similar result to that obtained when PLA2 activity was assayed under in vitro conditions (Figure 3 ). On the other hand, pretreatment of cells with indomethacin, an inhibitor of cyclo-oxygenase [20] , or NDGA, an inhibitor of lipoxygenase [23] , had no effect on PMAmediated arachidonic acid release. Moreover, when metabolites of the cyclo-oxygenase pathway (PGE2) or the lipoxygenase pathway (LTB4) were measured (Table 2) , it could be observed that mepacrine and heparin not only abolished PMA-mediated increases in their production, but also decreased metabolite concentrations below control levels, probably by reducing the amount of available arachidonic acid (Table 1) . Indomethacin could prevent the PMA-mediated increase in PGE2, while NDGA could prevent the PMA-mediated increase in LTB4.
The simplest explanation for all the above results is that mepacrine and heparin effectively inhibit PLA2 actiVity, perhaps by inhibition of translocation, while indomethacin and NDGA are capable of inhibiting either the cyclo-oxygenase or the lipoxygenase pathway of arachidonic acid metabolism. As inhibitors might also influence the PMA-mediated translocation of PKC from soluble to particulate fractions, the influence of these compounds on PKC activity was examined in a classical PKC histone kinase assay. As shown in Table 3 , none of the inhibitors Table 3 Effects of PMA and different inhibitors on PKC activity in bone marrow cells Bone marrow cells were treated for 45 min with PMA (500 nM), for 60 min with mepacrine (500 ,uM) plus heparin (1 mg/ml), indomethacin (50 ,M) or NDGA (50 4uM), or pretreated for 15 min with mepacrine (500 4M) plus heparin (1 mg/ml), indomethacin (50,M) or NDGA (50 uM) and then stimulated with PMA (500 nM) for 45 min. All other details are described in the Materials and methods section and the legend to influenced PMA-mediated translocation of PKC from the soluble to the particulate fraction in bone marrow cells. It is important to note that PKC-8, PKC-e and PKC-~could not be detected by the typical PKC histone kinase assay [24, 25] , and therefore Western blot analysis of PKC isoforms was performed using commercially available antibodies against the a, /J, y, e and C isoforms. As expected, PKC-y was not found in bone marrow cells, since it is known that this isoform is expressed only in the brain [1] . As shown in Figure 4 , all other isoforms were found associated with the particulate fraction of bone marrow cells (lane 1), as well as in the soluble fraction (results not shown), and their translocation to a membrane fraction could be stimulated by treatment of the cells with PMA (lane 3). PLA2 inhibitors did not influence the amounts of cPKCs and nPKCs associated with the particulate fraction in either control or PMA-treated bone marrow cells (Figure 4, lanes 2 and 4) . On the other hand, the pretreatment of cells with mepacrine and heparin lowered the PtdInsP3 may also be a PKC-activator [26] , we used wortmannin, an inhibitor of Ptdlns 3-kinase [27] , as a tool to prevent PtdInsP3 formation in the bone marrow cells. A 15 min pretreatment of cells with wortmannin (100 nM), which is known to be sufficient to inhibit Ptdlns 3-kinase and its physiological effects [27] , did not influence the amount of PKC-associated with the particulate fraction in control cells and could not abolish its PMA-mediated translocation (results not shown).
When grown in semi-solid medium containing an adequate supply of growth factors, bone marrow cells form colonies, which is used as a proliferation and differentiation test [7, 8] .
Therefore the effects of short-term exposure of cells to PMA, arachidonic acid and different inhibitors were investigated on the ability of murine bone marrow cells to form colonies in methylcellulose supplemented with an optimal level of cytokines. As shown in Table 4 In cells, two major groups of PLA2s are recognized: a lowmolecular-mass secretory PLA2 and a high-molecular-mass cytosolic PLA2 (cPLA2) [19] . The latter is known to be selective for arachidonic acid, to be activated by nanomolar concentrations of Ca2+ and to be insensitive to DTT [18, 19, 28] . Upon stimulation of various cell types with activators of PKC or protein tyrosine kinases (e.g. epidermal growth factor), cPLA2 is phosphorylated and translocated to cell membranes [28, 29] . Present Recently it has been demonstrated that cPLA2 activation depends on phosphorylation of serine-505 by mitogen-activated protein (MAP) kinase, which can be achieved through both PKC-dependent and PKC-independent mechanisms [30] . Moreover, it is known that, in leukaemic and haematopoietic cell lines, activation of the MAP kinase pathway by either granulocyte/ macrophage colony-stimulating factor (GM-CSF) or PKC will stimulate cell proliferation and differentiation [31] [32] [33] . This, together with evidence that macrophage colony-stimulating factor (M-CSF) and GM-CSF activate cPLA2 [34, 35] and the present observation of PMA-mediated activation of PLA2 which correlates with the increased ability of bone marrow cells to form colonies in vitro (a well known assay for both proliferation and differentiation), not only suggests a possible involvement of PKC-mediated activation of the MAP kinase pathway in the activation of PLA2 but also gives PLA2 an important role in the supported by using the putative PLA2 inhibitors heparin and mepacrine [20, 21] . Heparin has anti-proliferative effects on many cell types including endothelial cells [36] , Schwann cells [37] and muscle cells [38] where it inhibits the PKC-dependent pathway for proto-oncogene induction [39] , as well as MAP kinase activation [40] , while mepacrine blocks growth factor-and serumstimulated proliferation of endothelial and smooth muscle cells [41] . We observed that exposure of cells to these compounds inhibited more than 80 % of the initial PLA2 activity, diminished the release of arachidonic acid from the cells and abolished the increase in the number of colonies formed after treatment of the cells with PMA. Therefore current results corroborate the hypothesis formulated by Reilly et al. [42] that heparin regulates cell proliferation and that one possible mechanism is to inhibit, together with mepacrine, PLA2 activity.
PMA-sensitive PKCs are involved in mitogenic signal transduction in many cell systems [1] , although this does not appear to be a general phenomenon. Recently it has been observed that the PKC-C isoform, which is insensitive to PMA, is critical for mitogenic signal transduction and is associated in vitro with the MAP kinase pathway [43, 44] . Although the mechanisms of PKC-C activation are only partially understood, it is known that PtdInsP3 and unsaturated fatty acids can enhance PKC-C activity under in vitro conditions [25, 45, 46] . Since the pretreatment of cells with wortmannin did not influence the association of PKC-C with particulate fractions in control or PMA-stimulated bone marrow cells, it seems that in the experimental model used in this study and under in vivo conditions PtdInsP3 does not comprise a part of the signalling pathway leading to the activation of PKC-C. On the other hand, pretreatment of cells with mepacrine and heparin, which effectively inhibit PLA2 activity, reduced the amount of PKC-C associated with the particulate fraction in control cells and diminished the PMA-induced translocation of PKC-C. These observations correlate with the effects of these inhibitors on the ability of bone marrow cells to form colonies in vitro. Therefore it seems probable that in bone marrow cells PKC-C is important for mitogenic signal transduction, as has been shown in oocytes and fibroblasts [44] . In addition, in this experimental model the activation of PKC-C lies downstream to PLA2 activation, since exogenous addition of arachidonic acid caused translocation of PKC-C to the particulate fraction and increased the number of colonies formed, and neither effect was influenced by PLA2 inhibitors. It is also important to note that the pattern of translocation of PKC-C, as measured by Western blot analysis, should be interpreted with great caution, since antipeptide antibodies directed against the C-terminus of PKC-C may also recognize a newly described PKC-t, as well as a member of the cPKC subfamily which is thought to be distinct from either PKC-a or -,f [3, 25, 47] .
In conclusion, the present data suggest that PMA-mediated activation of cPKCs and nPKCs in bone marrow cells leads to PLA2 activation which, by releasing arachidonic acid from phospholipids, activates PKC-C; this signalling pathway appears to be mitogenic. As it is well known that PKC has an apparent role not only in the development but also in the lineage commitment of myeloid progenitor cells [48] , particularly in M-CSF-stimulated macrophage development from granulocyte/ macrophage colony-forming cells [49] , it will be of major importance to investigate the PMA-mediated signalling pathway in purified myeloid progenitor cells, as well as in leukaemia cell lines. The results obtained from signalling pathway studies should be correlated with the ability of cells to proliferate and differentiate, since PMA (present paper), M-CSF and GM-CSF [34, 35] share at least a part of a common signalling process which, by affecting cPLA2 and PKC-C, might not only control mitogenesis 169 control of nlitogenesis in bone marrow cells. This was further as has been suggested [43, 44] but also have a pivotal role in the development and lineage commitment of haematopoietic cells.
